Physician profile
David Johnson
NPI 1386669075
$998.77
in general payments reported to CMS, 2019-2025
20 companies · $92.03 in 2025
The $92.03 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2021: $189 · 2022: $51.31 · 2023: $437 · 2024: $98.16 · 2025: $92.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $196.53 | 2019-2023 | |
| Alcon Vision LLC | $131.91 | 2019-2025 | Rocklatan, Tryptyr, Clareon |
| Horizon Therapeutics Plc | $121.65 | 2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $92.99 | 2021 | |
| Glaukos Corporation | $68.85 | 2019-2025 | Idosetr |
| Bausch & Lomb Americas INC. | $65.80 | 2023-2025 | Vyzulta, Infuse, Miebo |
| Coopervision INC. | $56.42 | 2023-2024 | Misight Contact Lens, Myday Contact Lens |
| Shire North American Group INC | $36.30 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $32.70 | 2023 | Tecnis Iol |
| Genentech USA, INC. | $29.20 | 2025 | Vabysmo |
| Allergan, INC. | $27.79 | 2021 | |
| Harrow Eye, LLC | $19.71 | 2024 | Vevye |
| Abbvie INC. | $19.21 | 2022 | |
| Apellis Pharmaceuticals, INC. | $18.07 | 2023 | |
| Biotissue Holdings INC. | $16.19 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $16.18 | 2024 | |
| Kala Pharmaceuticals, INC. | $14.97 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $14.18 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $11.31 | 2021 | |
| Iridex Corporation | $8.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.